Results 161 to 170 of about 585,966 (213)

Current and future landscape of Bruton tyrosine kinase inhibitors in allergy. [PDF]

J Allergy Clin Immunol
Lin EV, Arce B, Alvarez-Arango S, Dispenza MC.   +3 more
europepmc   +1 more source

Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia. [PDF]

Discov Oncol
Hays P.
europepmc   +1 more source

Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data. [PDF]

J Manag Care Spec Pharm
Fitzgerald L, Ghosh S, Khan W, Bokun A, Lax A, Mu F, Cook EE, Chen J, Chen G, Wu E, Lin Y, Shi L, Qureshi ZP, Graf SA.   +13 more
europepmc   +1 more source

Outcomes of Bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia in US veterans with severe renal dysfunction. [PDF]

Br J Haematol
Lin C, Anderson CE, Scobie MR, Rodgers TD, Kelley MJ, Friedman DR.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Bruton’s Tyrosine Kinase in Ankylosing Spondylitis

Spine, 2023
Study Design. Prospective case-control study. Objective. To explore the role of Bruton’s tyrosine kinase (BTK) in ankylosing spondylitis (AS). Summary of Background Data.
Hsien-Tzung, Liao, Chun-Hsiung, Chen
openaire   +2 more sources

Role of Bruton's tyrosine kinase in immunodeficiency

Current Opinion in Immunology, 1994
The genetic defect associated with human X-linked agammaglobulinemia and murine X-linked immunodeficiency was recently shown to result from lack of function of a new cytoplasmic tyrosine kinase, called Bruton's tyrosine kinase (Btk). The phenotypes associated with these immunodeficiencies indicate that Btk plays a critical role in B-lymphocyte ...
David J Rawlings, Jung Wook Park, Satoshi Tsukada   +2 more
exaly   +3 more sources

Signalling of Bruton's Tyrosine Kinase, Btk

Scandinavian Journal of Immunology, 1999
Bruton's tyrosine kinase, which is encoded by the BTK gene, is a cytoplasmic protein tyrosine kinase (PTK) crucial for B‐cell development and differentiation. It belongs to the Tec family of PTKs containing several domains that are characteristic of signalling molecules.
A J, Mohamed, B F, Nore, B, Christensson, C I, Smith   +3 more
openaire   +2 more sources

Bruton Tyrosine Kinase Degraders

American Journal of Clinical Oncology
Bruton tyrosine kinase (BTK) is a key enzyme involved in B-cell development and signaling, making it a crucial target in the treatment of B-cell malignancies, such as chronic lymphocytic leukemia and non-Hodgkin lymphoma. While BTK inhibitors (BTKi), such as ibrutinib, have been effective, resistance—both intrinsic and acquired—poses a significant ...
Giorgi, Sabakhtarishvili, Mouza, Alshebli, Omer, Bajwa, Imad A, Tabbara   +3 more
openaire   +2 more sources

Resistance to Bruton Tyrosine Kinase Inhibitors

Hematology/Oncology Clinics of North America
Targeting Bruton tyrosine kinase (BTK) has revolutionized the therapy for chronic lymphocytic leukemia. As patients remain on therapy, however, resistance develops progressively over time. The most common mechanism of resistance to covalent BTK inhibitors is mutation of the C481 target residue to serine, abrogating covalent binding.
openaire   +2 more sources